Mushrooms and Metabolic Syndrome: Addressing All 5 Criteria

Mushrooms, Incretin Hormones & Metabolic Syndrome

4 of 5 criteria

A 2023 systematic review of human studies found mushroom consumption shows beneficial associations with four of the five metabolic syndrome diagnostic criteria — fasting glucose, HDL cholesterol, inflammation markers, and obesity indices.

Uffelman et al., Nutrients, 2023

37 MetS patients

ate 100g white button mushrooms daily for 16 weeks in the only study recruiting actual metabolic syndrome patients

4 species

maitake, reishi, cordyceps, and Agaricus blazei each have human clinical trial evidence for blood glucose lowering

No effect

on cardiovascular mortality or stroke — the Uffelman review's important null result

Uffelman et al., Nutrients, 2023

View as image ↗

Metabolic syndrome is a cluster diagnosis. It is not one disease but a combination of five specific measurements that together signal sharply elevated risk for cardiovascular disease and type 2 diabetes. Roughly one in three American adults meets the criteria.

The five diagnostic criteria are: excess abdominal fat (waist circumference above 35 inches for women or 40 inches for men), elevated fasting blood glucose (above 100 mg/dL), high blood pressure (at or above 130/85 mmHg), elevated triglycerides (at or above 150 mg/dL), and low HDL cholesterol (below 40 mg/dL for men or 50 mg/dL for women). Meet any three of five and the clinical definition applies. Unlike a condition with a single target, metabolic syndrome requires something that addresses multiple body systems at once.

A 2023 systematic review of human studies published in Nutrients examined mushroom consumption across cardiometabolic markers and found suggestive beneficial associations with at least four of the five criteria.^[1] This article organizes what the evidence shows, criterion by criterion, including where the data is thin and where a significant null result deserves mention.

For the species-by-species breakdown of clinical trial evidence on mushrooms and blood glucose specifically, the complete diabetes research guide covers the clinical landscape in detail.

Criterion 1 — Waist Circumference: The Study That Actually Recruited Metabolic Syndrome Patients

Every systematic review of mushrooms and cardiometabolic health draws on studies of generally healthy adults or diabetic populations. One study stands clearly apart from that pattern.

Calvo and colleagues (2016) ran a 16-week retrospective study in 37 adults who already met the diagnostic criteria for metabolic syndrome.^[2] Participants ate 100g of raw white button mushrooms (Agaricus bisporus) per day. The primary findings were biological, not clinical: ergothioneine levels doubled, an anti-inflammatory hormone called adiponectin increased significantly, and two measures of oxidative stress fell significantly.

Ergothioneine is an antioxidant amino acid found almost exclusively in mushrooms and certain other fungi. Human bodies cannot synthesize it, which means mushroom consumption is the primary dietary source for most people. Adiponectin is a hormone that fat cells produce. It improves the ability of other cells to respond to insulin and has protective effects on blood vessel walls. Adiponectin levels typically fall as body fat accumulates, making low adiponectin one of the biological features of metabolic syndrome itself. The Calvo cohort did not show significant weight loss from mushroom consumption, but the adiponectin increase and oxidative stress reduction point toward biological mechanisms that could, over longer timeframes, influence multiple metabolic syndrome criteria.

This study does not establish that eating button mushrooms reverses metabolic syndrome. It establishes something narrower but meaningful: real metabolic syndrome patients, eating a realistic quantity of a widely available mushroom, produce measurable biological changes in a direction consistent with metabolic syndrome management.

The broader systematic picture comes from Uffelman and colleagues (2023), who reviewed human research across cardiometabolic markers and found suggestive beneficial associations with obesity-related metrics including body weight, BMI, and waist circumference.^[1] These associations are described as suggestive rather than conclusive, and they are not uniform across studies, but they cover the abdominal obesity criterion more broadly than any single study can.

The gut microbiome mechanism underlying mushroom polysaccharides' effects on appetite and body composition is covered in detail in how mushroom polysaccharides affect gut hormones that regulate appetite.

Criterion 2 — Blood Glucose: Four Species, Decades of Evidence, and Two Distinct Mechanisms

The connection between mushrooms and blood glucose is the most documented relationship in this field. It is also the one with the strongest human trial foundation.

Lo and colleagues (2011) reviewed the historical evidence on medicinal mushrooms for glycemic control and found consistent hypoglycemic activity documented for maitake (Grifola frondosa), reishi (Ganoderma lucidum), cordyceps, and Agaricus blazei across preclinical and early clinical research.^[3] The review noted a persistent gap between the depth of preclinical evidence and the quality of available human trials. The gap existed, but the breadth of species showing consistent glucose effects was notable.

Lindequist and colleagues (2020) updated that picture with a review focused specifically on human clinical trials.^[4] The same four species appeared with confirmed hypoglycemic effects in human studies. Evidence quality varies considerably across species and study designs; some trials were small or uncontrolled. But each of the four species has human trial data, which places mushroom blood-glucose research in a different category from most botanical supplement claims.

Das and colleagues (2022) added a mechanistic layer that matters for understanding how these effects work.^[5] They distinguished two types of blood-glucose-lowering activity in mushroom compounds. The first type stimulates the pancreas to release more insulin. The second type makes cells more responsive to insulin that already exists in the bloodstream, without requiring the pancreas to produce more. Beta-glucans, triterpenoids, and polysaccharides from different mushroom species appear to operate at different points in this system. This distinction matters because a patient whose pancreas still functions well needs a different intervention than one whose pancreas is exhausted but whose cells have become unresponsive.

One species outside the standard quartet is worth noting. Ratnaningtyas and colleagues (2022) documented both antidiabetic and antioxidant activity in Coprinus comatus, the shaggy ink cap, in a preclinical model.^[6] The shaggy ink cap is edible, common in temperate regions, and almost entirely absent from metabolic syndrome research coverage. The evidence remains preclinical. But it expands the species picture beyond the four most-studied candidates.

For a deeper look at maitake clinical trial data specifically, including the SX-fraction work, see maitake and type 2 diabetes: the SX-fraction clinical trials. For the mechanistic detail on how incretin hormones including GLP-1 connect mushroom consumption to blood sugar regulation, see mushroom compounds and incretin hormones: GLP-1 and GIP research.

Criterion 3 — Blood Pressure: Plausible Mechanism, Thin Human Trial Evidence

Blood pressure is where the mushroom evidence is mechanistically coherent and clinically limited.

Kundakovic and colleagues (2013) mapped the bioactive compounds in edible mushrooms to each of the five metabolic syndrome criteria and placed triterpenes in the blood pressure column.^[7] Triterpenes are a class of compounds found in high concentrations in reishi and present in smaller amounts in other species. They inhibit an enzyme called ACE, the angiotensin-converting enzyme, which sits at a key step in a hormonal chain that constricts blood vessels and raises blood pressure. ACE inhibition is also the mechanism of an entire class of pharmaceutical blood pressure medications, which gives the mechanistic case some external credibility.

Tung and colleagues (2020) catalogued hypotensive activity as one of the documented effects of edible mushroom compounds, alongside hypoglycemic, triglyceride-lowering, and weight-managing activities across multiple species and extract types.^[8]

The limitation is direct: most of the blood pressure evidence sits in preclinical models and mechanism reviews. Human clinical trials measuring blood pressure as a primary endpoint in metabolic syndrome patients eating mushrooms are sparse. The mechanistic case is biologically coherent and supported by preclinical data, but human trial evidence for blood pressure is weaker than for any of the other four criteria. This gap is worth stating plainly rather than glossing over.

Criterion 4 — Triglycerides: Reishi's Meta-Analysis and the Hepatic Mechanism

Elevated triglycerides, the form in which the body stores unused dietary calories as fat, are the fourth metabolic syndrome criterion. They sit above 150 mg/dL in metabolic syndrome and are independently associated with cardiovascular risk.

Aref and colleagues (2023) published a systematic review and meta-analysis examining Ganoderma lucidum (reishi) and lipid profiles in animal studies.^[9] Pooling results across multiple studies, the analysis found that reishi consistently reduced total cholesterol, LDL cholesterol, and triglycerides. A meta-analysis provides a more reliable estimate of effect size than any individual study because it averages across the variability of individual experiments. The reishi triglyceride data held up across the pooled analysis. The caveat is that all included studies were in animal models, and human trial evidence for reishi's effect on triglycerides is more limited and less consistent.

Tung and colleagues (2020) placed triglyceride-lowering activity on a broader list of metabolic effects documented for edible mushrooms, identifying beta-glucans and triterpenes as the primary compound classes responsible.^[8]

Kundakovic and colleagues (2013) identified eritadenin, a sulfur-containing compound found specifically in shiitake mushrooms, as a cholesterol-lowering agent.^[7] Eritadenin works by inhibiting an enzyme involved in cholesterol synthesis in the liver. Its primary target is total cholesterol and LDL rather than triglycerides directly, but both markers are part of the lipid profile relevant to metabolic and cardiovascular risk.

The full picture of maitake's lipid-lowering effects, including the mechanism by which it suppresses a key enzyme in hepatic fat production, is covered in maitake and metabolic regulation: beyond blood sugar to full metabolic health.

Criterion 5 — HDL Cholesterol: The Direction Is Right, the Evidence Is Thinner

HDL cholesterol is the protective fraction. Low HDL is a metabolic syndrome criterion because low levels correlate with higher cardiovascular risk. Raising HDL is notoriously difficult; some pharmaceutical compounds developed specifically to raise HDL failed to reduce cardiovascular events even when they successfully raised the number on a blood panel.

Uffelman and colleagues (2023) found that mushroom consumption shows a suggestive beneficial association with HDL cholesterol in human studies.^[1] The systematic review placed HDL alongside fasting glucose, hs-CRP, and obesity indices as the markers with the most consistent directional signal across the human literature.

Krittanawong and colleagues (2021) reviewed cardiovascular health specifically and identified two mushroom compounds most strongly linked to improved lipid profiles: beta-glucan and ergothioneine.^[10] Beta-glucans are soluble fibers in mushroom cell walls. In the gut, they bind bile acids and reduce the amount reabsorbed back into circulation. This forces the liver to pull more cholesterol from the blood to produce new bile acids, which lowers LDL and can modestly raise HDL as a secondary effect. Ergothioneine's role in the lipid picture is different: as an antioxidant, it appears to protect HDL particles from oxidative damage, which affects how well HDL functions rather than just how much of it circulates.

The evidence for HDL specifically is less direct than for triglycerides or blood glucose. The associations are present in the data, but the human trial evidence is thinner and less mechanistically specific for HDL than for the other four criteria. This is where the evidence base is earliest in its development.

The Five-Criteria Map: Best-Evidenced Mushroom for Each

The table below organizes the research by criterion, identifying the best-evidenced mushroom for each marker, the primary bioactive responsible, and the strongest evidence type currently available.

A broader comparison of mushroom species by their relative strength of evidence for metabolic and diabetes management is available at comparing mushroom species for diabetes management: which has the strongest evidence?.

What the Evidence Establishes — and the Null Result That Matters

Uffelman and colleagues (2023) set the current ceiling on what mushroom consumption research can claim for human cardiometabolic health.^[1] The systematic review found suggestive associations with fasting blood glucose, HDL-C, hs-CRP, and obesity metrics. That is a meaningful finding across four criteria, in the same direction, across studies of actual human populations.

The null result is equally important: the review found no significant effect of mushroom consumption on cardiovascular mortality or stroke in available human studies. This matters because reducing cardiovascular events is the ultimate goal of treating metabolic syndrome. Metabolic markers like blood glucose and triglycerides are intermediate outcomes, meaning they sit on the pathway toward heart attack and stroke. But the evidence does not establish that the marker improvements from mushroom consumption translate into fewer events. That would require longer-term outcome data in large populations. That data does not yet exist.

Kundakovic and colleagues (2013) and Tung and colleagues (2020) provide the most comprehensive mechanistic frameworks for why mushrooms affect these markers, cataloguing the full range of bioactive classes and their biological targets across the metabolic syndrome criteria.^[7],[8] Mechanism explains the how. It does not resolve whether the effect size is large enough to matter clinically over the decade-scale timeline of chronic disease development.

The honest position: mushrooms show biological effects across multiple metabolic syndrome markers. The effects are consistent with the direction that metabolic syndrome management aims for. Whether those effects accumulate into meaningful reductions in cardiovascular disease and diabetes risk with years of regular consumption has not been tested.

The GLP-1 and incretin hormone connection, which represents the most mechanistically complete pathway currently described for how mushroom consumption affects metabolic syndrome markers, is covered in mushrooms and GLP-1: can fungi mimic the Ozempic effect?.

The Bottom Line

Mushroom consumption shows suggestive beneficial associations with at least four of the five metabolic syndrome diagnostic criteria in human research. Blood glucose has the strongest evidence base, with human clinical trial data confirmed across four species. Blood pressure has the weakest human trial evidence despite a plausible mechanistic case. The 2023 Uffelman systematic review found no significant effect on cardiovascular mortality or stroke, meaning the downstream clinical endpoints that metabolic syndrome treatment ultimately aims to prevent remain unestablished in the mushroom literature.

Frequently Asked Questions

Can mushrooms help with metabolic syndrome?

Research shows mushrooms may affect several metabolic syndrome markers, but current evidence is suggestive rather than definitive. The 2023 Uffelman systematic review of human studies found beneficial associations with four of the five criteria — fasting blood glucose, HDL cholesterol, inflammation markers, and obesity indices — while finding no significant effect on cardiovascular mortality or stroke, the outcomes that metabolic syndrome treatment ultimately aims to prevent.

Which mushroom is best for metabolic syndrome?

No single mushroom addresses all five metabolic syndrome criteria equally. Maitake (Grifola frondosa) has the strongest human clinical trial evidence for blood glucose. Reishi (Ganoderma lucidum) has the best-documented evidence for triglycerides and cholesterol, though mainly from animal studies. White button mushrooms (Agaricus bisporus) are the only species tested directly in actual metabolic syndrome patients (Calvo 2016, n=37). The evidence suggests different species may be most relevant for different criteria.

Do mushrooms lower triglycerides?

Animal study evidence suggests they can. A 2023 meta-analysis by Aref and colleagues found reishi (Ganoderma lucidum) consistently reduced total cholesterol, LDL, and triglycerides across multiple animal models. Human trial evidence for triglycerides specifically is more limited. Beta-glucans and triterpenes are the compound classes most associated with this effect in the research literature.

Can eating mushrooms lower blood pressure?

The mechanistic case is plausible: triterpenes in mushrooms, particularly reishi, inhibit an enzyme (ACE) that is involved in blood vessel constriction, using the same mechanism as an entire class of pharmaceutical blood pressure drugs. However, human clinical trial evidence for blood pressure as a primary endpoint in mushroom studies is sparse. The blood pressure evidence is the thinnest of the five metabolic syndrome criteria in the human literature.

Do mushrooms improve HDL cholesterol?

The 2023 Uffelman systematic review found a suggestive beneficial association between mushroom consumption and HDL cholesterol in human studies. The proposed mechanisms involve beta-glucans reducing bile acid reabsorption (which indirectly raises HDL) and ergothioneine protecting HDL particles from oxidative damage. The human evidence for HDL specifically is less direct and less consistent than for blood glucose or obesity markers.

How many mushrooms should you eat for metabolic syndrome?

The one human study conducted in actual metabolic syndrome patients used 100g of raw white button mushrooms per day over 16 weeks and found significant changes in ergothioneine levels, adiponectin, and oxidative stress markers. Most other human research involves culinary quantities as part of regular diet rather than therapeutic doses. Research doses vary by species and study, and no standard clinical protocol exists for metabolic syndrome management.

Sources & References

1. 1RTHM-01810·Uffelman, Cassi N et al. (2023). “An Assessment of Mushroom Consumption on Cardiometabolic Disease Risk Factors and Morbidities in Humans: A Systematic Review..” Nutrients.Study breakdown →PubMed →↩
2. 2RTHM-00767·Calvo, Mona S et al. (2016). “A Retrospective Study in Adults with Metabolic Syndrome: Diabetic Risk Factor Response to Daily Consumption of Agaricus bisporus (White Button Mushrooms)..” Plant foods for human nutrition (Dordrecht.Study breakdown →PubMed →↩
3. 3RTHM-00418·Lo, Hui-Chen et al. (2011). “Medicinal mushrooms for glycemic control in diabetes mellitus: history, current status, future perspectives, and unsolved problems (review)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
4. 4RTHM-00632·Lindequist, Ulrike et al. (2020). “Medicinal Mushrooms for Treatment of Type 2 Diabetes: An Update on Clinical Trials..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
5. 5RTHM-01500·Das, Arpita et al. (2022). “Medicinal Components in Edible Mushrooms on Diabetes Mellitus Treatment..” Pharmaceutics.Study breakdown →PubMed →↩
6. 6RTHM-00793·Ratnaningtyas, Nuniek Ina et al. (2022). “Ethanol extract of the mushroom Coprinus comatus exhibits antidiabetic and antioxidant activities in streptozotocin-induced diabetic rats..” Pharmaceutical biology.Study breakdown →PubMed →↩
7. 7RTHM-00294·Kundaković, Tatjana et al. (2013). “Therapeutic properties of mushrooms in managing adverse effects in the metabolic syndrome..” Current topics in medicinal chemistry.Study breakdown →PubMed →↩
8. 8RTHM-00660·Tung, Yu-Tang et al. (2020). “Edible Mushrooms: Novel Medicinal Agents to Combat Metabolic Syndrome and Associated Diseases..” Current pharmaceutical design.Study breakdown →PubMed →↩
9. 9RTHM-01656·Aref, Maryam et al. (2023). “Effect of Ganoderma lucidum on serum lipid profiles: A systematic review and meta-analysis on animal studies..” Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.Study breakdown →PubMed →↩
10. 10RTHM-01376·Krittanawong, Chayakrit et al. (2021). “Mushroom Consumption and Cardiovascular Health: A Systematic Review..” The American journal of medicine.Study breakdown →PubMed →↩